Belizatinib (TSR-011) is an orally active, potent inhibitor of ALK and TRKA , TRKB , and TRKC , with IC 50 of 0.7 nM for wild-type recombinant ALK kinase.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Pain | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Trk Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.